Home > Insider Trading > Filing (0001548538-14-000012)

Filing Details

Accession Number:: 0001548538-14-000012
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-06-11 17:29:04
Reporting Period:: 2014-06-09

Filing Date:: 2014-06-11
Accepted Time:: 2014-06-11 17:29:04
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1302573	Oncomed Pharmaceuticals Inc	OMED	Pharmaceutical Preparations (2834)	383572512

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1225480	D Jonathan Root	2735 Sand Hill Road Menlo Park CA 94025		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-06-09	5,476	$24.62	30,606	No	4	S	Indirect	Directly owned by EP VIII-A
Common Stock	Disposition	2014-06-09	2,776	$24.62	15,513	No	4	S	Indirect	Directly owned by EP VIII-B
Common Stock	Disposition	2014-06-10	3,186	$24.48	21,944	No	4	S	Indirect	Directly owned by EP VIII-A
Common Stock	Disposition	2014-06-10	1,614	$24.48	11,123	No	4	S	Indirect	Directly owned by EP VIII-B

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	Directly owned by EP VIII-A
No	4	S	Indirect	Directly owned by EP VIII-B
No	4	S	Indirect	Directly owned by EP VIII-A
No	4	S	Indirect	Directly owned by EP VIII-B

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.21 to $24.99, inclusive for sales made on June 9, 2014, and prices ranging from $23.95 to $24.85, inclusive for sales made on June 10, 2014. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The reported securities are owned directly by each of U.S. Venture Partners VIII, L.P. ("USVP VIII"), USVP VIII Affiliates Fund, L.P. ("AFF VIII"), USVP Entrepreneur Partners VIII-A, L.P. ("EP VIII-A") and USVP Entrepreneur Partners VIII-B, L.P. ("EP VIII-B" and together with USVP VIII, AFF VIII and EP VIII-A, the "USVP VIII Funds"). Presidio Management Group VIII, L.L.C. ("PMG VIII") is the general partner of each of USVP VIII, AFF VIII, EP VIII-A and EP VIII-B and may be deemed to have sole voting and dispositive power over the shares held by the USVP VIII Funds. PMG VIII and each of Irwin Federman, Steven M. Krausz, David Liddle, Jonathan D. Root, Casey M. Tansey and Philip M. Young, the managing members of PMG VIII who may be deemed to share voting and dispositive power over the reported securities, disclaim beneficial ownership of the reported securities held by the USVP VIII Funds except to the extent of any pecuniary interest therein.